Pictured: Thong Q. Le (left) and Paul Sekhri (right), the newest members of the Board of Directors for Deep Genomics
Cambridge, Mass. / Toronto, CA - October 6, 2025 - Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic medicines with its AI foundation model platform, today announced the appointment of respected business leaders Thong Q. Le and Paul Sekhri to its Board of Directors.
“We feel incredibly lucky to have the talents of Thong and Paul join our Board of Directors”, said Brian O’Callaghan, Chief Executive Officer of Deep Genomics. “Their collective decades of experience shaping the life sciences and biotechnology industry will be invaluable as we continue towards our mission of delivering AI-powered genetic medicines to patients.”
Thong Q. Le brings more than two decades of investment experience in the life sciences industry, with a strong track record of making impactful investments that improve lives, shaping effective investment strategies and aiding deal-making processes. Mr. Le currently serves as investment director and managing partner of the Strategic Investment Fund (SIF) for the Gates Foundation. Mr. Le also serves as chairman of Accelerator Life Science Partners (ALSP), a venture capital firm focused on developing next-generation life science companies. He has served as a director, founding president and CEO of more than a dozen ALSP portfolio companies, including Petra Pharma, Rodeo Therapeutics and Lodo Therapeutics. Mr. Le currently serves on several private biotech and nonprofit organization boards.
“In my time working with this industry, I’ve seen firsthand how the right combination of science, technology and leadership can transform what’s possible in drug discovery,” said Mr. Le. “Deep Genomics has all of those ingredients, and I’m thrilled to have this opportunity to help guide its continued growth.”
Paul Sekhri is the current Chair, President and CEO of vTv Therapeutics Inc., Chair of the Board of Resolution Therapeutics, and Executive Chair of Violet Therapeutics Inc., bringing more than 35 years of experience in business development and strategy across top life sciences, pharmaceutical and biotechnology companies. Most recently, he served as President and CEO of eGenesis Inc. and Lycera Corp. Previously, Mr. Sekhri held senior leadership positions at Sanofi, Teva Pharmaceuticals, TPG Biotech, Cerimon Pharmaceuticals Inc., Ariad Pharmaceuticals and Novartis. He currently serves on the Board of Veeva Systems, AdhereTech Inc., Kayothera; is Chair of Young Concert Artists (YCA), and sits on the Advisory Council of the New York Philharmonic.
Mr. Sekhri commented, “I am excited to be joining the Deep Genomics Board at such a pivotal time in therapeutics, and I remain inspired by their ability to advance a new generation of medicines with the power of AI. I look forward to contributing to such important TechBio advancements alongside this talented team.”
To learn more about Deep Genomics’ work and its groundbreaking impact in the realm of genomic R&D, visit www.deepgenomics.com. For those interested in joining this team of TechBio innovators, visit https://www.deepgenomics.com/careers/.
About Deep Genomics
Deep Genomics is a multidisciplinary team of AI and biology scientists dedicated to pioneering a new era of genomic research and development through its AI foundation models platform. Leveraging cutting-edge AI technologies and biological insights, Deep Genomics is revolutionizing drug discovery and development. Through its innovative approach and collaborative partnerships, Deep Genomics aims to accelerate the delivery of life-changing genetic medicines to patients worldwide. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow us on LinkedIn and Twitter.
Media Contact
Mandy Mellinger
Fight or Flight
deepgenomics@fightorflight.com